{
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.",
                "publication_date": "2025-04-15T14:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7269",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback",
                "url": "https://finance.yahoo.com/news/nvo-lly-gpcr-vktx-stocks-140000975.html"
            },
            {
                "headline": "We recently published a list of Biotech Stocks Dominate Monday\u2019s Top 10 Gainers. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other biotech stocks that dominate Monday\u2019s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street\u2019s major [\u2026]",
                "publication_date": "2025-04-15T04:40:28.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Why Viking Therapeutics, Inc.\u00a0(VKTX) Skyrocketed On Monday?",
                "url": "https://finance.yahoo.com/news/why-viking-therapeutics-inc-vktx-044028854.html"
            },
            {
                "headline": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts \u201climited reaction\u201d in Pfizer\u2019s shares following the news, JPMorgan tells investors that the decision is \u201cmostly a positive\u201d for Structure and Viking, both developing drugs in the",
                "publication_date": "2025-04-15T14:35:25.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
                "url": "https://finance.yahoo.com/news/smaller-obesity-drugmakers-jump-pfizer-143525028.html"
            },
            {
                "headline": "BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of liver injury seen in the phase 1 study. The firm points out that it has argued that this program has received almost too much attention \u2013 not because obesity isn\u2019t important, but because this was only phase 1 data. Without danuglipron, Pfizer\u2019s obesity pipeline now consists of a GIP receptor antagonist in phase 2 and a phase 1 oral GLP-1 in T2D with Nxera Pharma.",
                "publication_date": "2025-04-15T15:05:32.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7269",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged",
                "url": "https://finance.yahoo.com/news/bofa-keeps-neutral-pfizer-danuglipron-150532621.html"
            },
            {
                "headline": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City\u2019s Housing ShortagePresident Donald Trump\u2019s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade",
                "publication_date": "2025-04-15T03:32:37.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5994",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Trump Initiates Chips and Drug Probes\u00a0Ahead of More Tariffs",
                "url": "https://finance.yahoo.com/news/trump-announces-chips-drug-probes-204108780.html"
            },
            {
                "headline": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
                "publication_date": "2025-04-15T16:57:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
                "url": "https://finance.yahoo.com/news/pfizer-halts-obesity-pill-development-165700605.html"
            }
        ],
        "avgScore": 0.005714285714285687
    },
    "4 14 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of the 11 Best Dividend Paying Stocks According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best dividend-paying stocks. Dividend-paying stocks have consistently attracted investor interest due to their long-term value. CNBC highlights this by examining the [\u2026]",
                "publication_date": "2025-04-14T14:21:15.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9485",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer Inc. (PFE) Among the Best Dividend Paying Stocks According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-among-best-142115898.html"
            },
            {
                "headline": "Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Chevron Corporation (CVX) and Stryker Corporation (SYK), as well as two micro-cap stocks Value Line, Inc. (VALU) and Sypris Solutions, Inc. (SYPR).",
                "publication_date": "2025-04-14T21:15:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Top Analyst Reports for Bank of America, Chevron & Stryker",
                "url": "https://finance.yahoo.com/news/top-analyst-reports-bank-america-211500618.html"
            },
            {
                "headline": "Stocks are looking to extend their strongest weekly rally since late 2023.",
                "publication_date": "2025-04-14T10:09:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "TheStreet",
                "ticker": "PFE",
                "title": "Stock Market Today: Stocks end higher, tech stalls amid tariff confusion",
                "url": "https://finance.yahoo.com/news/stock-market-today-stocks-higher-100900834.html"
            },
            {
                "headline": "Pfizer tanks after liver injury kills obesity pill hopes--Lilly, Novo, and Viking surge as investors jump ship",
                "publication_date": "2025-04-14T15:18:31.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.743",
                "source": "GuruFocus.com",
                "ticker": "PFE",
                "title": "Pfizer's $130B Weight-Loss Dream Just Collapsed",
                "url": "https://finance.yahoo.com/news/pfizers-130b-weight-loss-dream-151831937.html"
            },
            {
                "headline": "Pfizer Inc. will stop developing an obesity pill after the treatment was linked to a potentially drug-related liver injury in a clinical trial patient. The company won't advance the once-daily medicine into the final stage of testing and will instead invest in earlier-stage treatments for obesity. Damian Garde reports on Bloomberg Television.",
                "publication_date": "2025-04-14T14:06:56.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.6124",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Pfizer Abandons Obesity Pill After Trial Liver Injury",
                "url": "https://finance.yahoo.com/video/pfizer-abandons-obesity-pill-trial-140656016.html"
            },
            {
                "headline": "Pfizer  is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant.  The company said Monday the stoppage comes after it reviewed clinical data and a study subject developed a liver injury that might have been caused by the drug, called danuglipron.  Halting the drug\u2019s development means  Pfizer  still is unable to get a cut, for now, of the white-hot obesity market, which analysts say could reach $100 billion by the end of the decade.",
                "publication_date": "2025-04-14T14:36:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5719",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Pfizer Halts Development of Weight-Loss Pill",
                "url": "https://finance.yahoo.com/m/b3673b54-a975-32c1-a871-82025800a9e7/pfizer-halts-development-of.html"
            }
        ],
        "avgScore": -0.02610434782608697
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.\u2019s comments on the company\u2019s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine\u2019s single-antigen composition as the reason for the push back, adding that the FDA is \u201cshifting our priorities to multiple-antigen vaccines.\u201d SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit",
                "publication_date": "2025-04-11T15:20:14.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7506",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "Novavax slides after RFK Jr. casts doubts about COVID vaccine",
                "url": "https://finance.yahoo.com/news/novavax-slides-rfk-jr-casts-152014610.html"
            },
            {
                "headline": "We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other cheap NYSE stocks. On March 26, Jack Caffrey of JPMorgan Asset Management provided an analysis of market trends in [\u2026]",
                "publication_date": "2025-04-11T20:35:07.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3612",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer Inc. (PFE) A Cheap NYSE Stock to Invest in According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-cheap-nyse-203507561.html"
            },
            {
                "headline": "Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.",
                "publication_date": "2025-04-11T07:06:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility",
                "url": "https://finance.yahoo.com/news/6-stocks-clear-price-dislocations-070600692.html"
            },
            {
                "headline": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-04-11T13:00:14.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock",
                "url": "https://finance.yahoo.com/news/know-beyond-why-pfizer-inc-130014887.html"
            },
            {
                "headline": "Pfizer (PFE) closed the most recent trading day at $21.91, moving +1.48% from the previous trading session.",
                "publication_date": "2025-04-11T21:45:16.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer (PFE) Advances But Underperforms Market: Key Facts",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-advances-underperforms-market-214516632.html"
            },
            {
                "headline": "Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.",
                "publication_date": "2025-04-11T07:06:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility",
                "url": "https://finance.yahoo.com/news/6-stocks-clear-price-dislocations-070600692.html"
            }
        ],
        "avgScore": 0.18994000000000003
    },
    "4 10 2025": {
        "importantArticles": [
            {
                "headline": "PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.",
                "publication_date": "2025-04-10T13:44:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8225",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?",
                "url": "https://finance.yahoo.com/news/pfizer-stock-falls-52-week-134400344.html"
            },
            {
                "headline": "NEW YORK, April 10, 2025--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.",
                "publication_date": "2025-04-10T15:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24",
                "url": "https://finance.yahoo.com/news/pfizer-invites-shareholders-attend-virtual-150000793.html"
            },
            {
                "headline": "A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains.",
                "publication_date": "2025-04-10T17:11:04.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6249",
                "source": "StockStory",
                "ticker": "PFE",
                "title": "Select Medical, Phreesia, Eli Lilly, Pfizer, and Brink's Shares Are Falling, What You Need To Know",
                "url": "https://finance.yahoo.com/news/select-medical-phreesia-eli-lilly-171104703.html"
            },
            {
                "headline": "Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",
                "publication_date": "2025-04-10T16:58:23.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "S&P, Dow Jones Pharma Names Rattled \u2014 Again \u2014 On Trump's Tariffs Whiplash",
                "url": "https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s-p-dow-jones-pharma-names.html"
            },
            {
                "headline": "The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.",
                "publication_date": "2025-04-10T17:07:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.25",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Vaxcyte Stock Plummets 56% in a Month: Here's the Reason",
                "url": "https://finance.yahoo.com/news/vaxcyte-stock-plummets-56-month-170700030.html"
            },
            {
                "headline": "Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might \"go wild\" on biotech stocks.",
                "publication_date": "2025-04-10T16:01:52.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.",
                "url": "https://finance.yahoo.com/m/ad410584-ce11-3244-a597-6a1760bc9030/trump-wants-rfk-jr-to-go.html"
            }
        ],
        "avgScore": 0.18951249999999997
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, JD, PFE, STNE and ENS are some such stocks.",
                "publication_date": "2025-04-09T12:58:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7506",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "5 Low Price-to-Book Stocks to Add to Your Portfolio in April",
                "url": "https://finance.yahoo.com/news/5-low-price-book-stocks-125800063.html"
            },
            {
                "headline": "Catalysts host Madison Mills and Trader Talk podcast host Kenny Polcari take a look at some of the day's top trending stocks. Apple (AAPL) is in focus after Microsoft (MSFT) replaced Apple as the most valuable company. Alibaba (BABA) reverses earlier gains after US tariffs went into effect. Drugmaker stocks, including Pfizer (PFE), Merck (MRK), and Eli Lilly (LLY), are falling after President Trump announced that pharmaceutical tariffs may be on the way. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
                "publication_date": "2025-04-09T14:43:22.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7178",
                "source": "Yahoo Finance Video",
                "ticker": "PFE",
                "title": "Apple, Alibaba, drugmaker stocks: Trending Tickers",
                "url": "https://finance.yahoo.com/video/apple-alibaba-drugmaker-stocks-trending-144322260.html"
            },
            {
                "headline": "If you're a dividend investor, now can be an ideal time to go bargain-hunting.  The stock market is in the midst of a broad sell-off, with investors dumping all types of stocks, both bad ones and good ones.  Three dividend stocks that are near their 52-week lows and which may make for solid income-generating investments are Pfizer (NYSE: PFE), Lockheed Martin (NYSE: LMT), and Rogers Communications (NYSE: RCI).",
                "publication_date": "2025-04-09T09:32:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.0772",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now",
                "url": "https://finance.yahoo.com/news/3-high-yielding-dividend-stocks-093200831.html"
            },
            {
                "headline": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer were all down at least 2.5% in Wednesday midday trading.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK fell 2% or more in the U.S.",
                "publication_date": "2025-04-09T13:51:17.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7506",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
                "url": "https://finance.yahoo.com/m/f171bfb7-94e2-3b98-bde2-9d5add357a5c/novo-nordisk-abbvie-stocks.html"
            },
            {
                "headline": "David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...",
                "publication_date": "2025-04-09T13:00:15.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5778",
                "source": "Simply Wall St.",
                "ticker": "PFE",
                "title": "Is Pfizer (NYSE:PFE) A Risky Investment?",
                "url": "https://finance.yahoo.com/news/pfizer-nyse-pfe-risky-investment-130015999.html"
            },
            {
                "headline": "Drugmaker stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE), are under pressure on Wednesday after President Trump announced that he may impose tariffs on pharmaceutical imports. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
                "publication_date": "2025-04-09T14:11:57.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Yahoo Finance Video",
                "ticker": "PFE",
                "title": "Trump says pharmaceutical tariffs may be coming: What to know",
                "url": "https://finance.yahoo.com/video/trump-says-pharmaceutical-tariffs-may-141157823.html"
            }
        ],
        "avgScore": -0.1271
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "publication_date": "2025-04-08T13:40:10.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9081",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Is Pfizer (PFE) Stock Undervalued Right Now?",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-stock-undervalued-now-134010049.html"
            },
            {
                "headline": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
                "publication_date": "2025-04-08T13:08:17.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7717",
                "source": "Investing.com",
                "ticker": "PFE",
                "title": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
                "url": "https://finance.yahoo.com/news/goldman-turns-cautious-major-pharma-130817424.html"
            },
            {
                "headline": "The narrative around Pfizer couldn't be much worse. That makes the stock very interesting at these prices.",
                "publication_date": "2025-04-08T08:40:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6754",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Down 62%, Should You Buy the Dip on Pfizer?",
                "url": "https://finance.yahoo.com/news/down-62-buy-dip-pfizer-084000869.html"
            },
            {
                "headline": "Pfizer  stock fell to the lowest closing price since 2012, putting its yield near 8%, after cautious comments from a  UBS  analyst ahead of the company\u2019s quarterly earnings on April 29.  Pfizer shares declined 3.5% to $21.84 after hitting a new 52-week low of $21.44.  All that has resulted in a generation of frustration for investors in what once was the top drug company in the world by market value.",
                "publication_date": "2025-04-08T21:26:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Barrons.com",
                "ticker": "PFE",
                "title": "Pfizer Stock\u2019s Fall to \u201997 Level Lifts Yield Near 8%. Dividend Looks Safe.",
                "url": "https://finance.yahoo.com/m/21c833dc-2b10-33f0-afe2-439fc5c81233/pfizer-stock%E2%80%99s-fall-to-%E2%80%9997.html"
            },
            {
                "headline": "Goldman updates coverage across major U.S. drugmakers, citing exclusivity risks, pricing power, and pipeline outlooks",
                "publication_date": "2025-04-08T17:58:13.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2732",
                "source": "GuruFocus.com",
                "ticker": "PFE",
                "title": "Biopharma Shakeup: Goldman Boosts J&J, Eli Lilly While Flagging Risks at Pfizer and AbbVie",
                "url": "https://finance.yahoo.com/news/biopharma-shakeup-goldman-boosts-j-175813148.html"
            },
            {
                "headline": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
                "publication_date": "2025-04-08T13:15:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
                "url": "https://finance.yahoo.com/news/abbvies-rinvoq-gets-eu-nod-131500800.html"
            }
        ],
        "avgScore": 0.3437333333333333
    },
    "coef": -0.6,
    "avgCoef": 0.16753050520976348
}